Original Article
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
N Engl J Med 2006; 355:1525-1538October 12, 2006
- Abstract
Background
Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease.
Methods
In this 42-site, double-blind, placebo-controlled trial, 421 outpatients with Alzheimer's disease and psychosis, aggression, or agitation were randomly assigned to receive olanzapine (mean dose, 5.5 mg per day), quetiapine (mean dose, 56.5 mg per day), risperidone (mean dose, 1.0 mg per day), or placebo. Doses were adjusted as needed, and patients were followed for up to 36 weeks. The main outcomes were the time from initial treatment to the discontinuation of treatment for any reason and the number of patients with at least minimal improvement on the Clinical Global Impression of Change (CGIC) scale at 12 weeks.
Results
There were no significant differences among treatments with regard to the time to the discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), quetiapine (median, 5.3 weeks), risperidone (median, 7.4 weeks), and placebo (median, 8.0 weeks) (P=0.52). The median time to the discontinuation of treatment due to a lack of efficacy favored olanzapine (22.1 weeks) and risperidone (26.7 weeks) as compared with quetiapine (9.1 weeks) and placebo (9.0 weeks) (P=0.002). The time to the discontinuation of treatment due to adverse events or intolerability favored placebo. Overall, 24% of patients who received olanzapine, 16% of patients who received quetiapine, 18% of patients who received risperidone, and 5% of patients who received placebo discontinued their assigned treatment owing to intolerability (P=0.009). No significant differences were noted among the groups with regard to improvement on the CGIC scale. Improvement was observed in 32% of patients assigned to olanzapine, 26% of patients assigned to quetiapine, 29% of patients assigned to risperidone, and 21% of patients assigned to placebo (P=0.22).
Conclusions
Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease. (ClinicalTrials.gov number, NCT00015548.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Discontinuation of Treatment in Phase 1 According to Study Group.Article Activity
- Article
Delusions, hallucinations, aggression, and agitation affect more than half of patients with Alzheimer's disease and related dementias.1-4 Antipsychotic drugs are used to treat these behaviors and symptoms and are among the most frequently used psychotropic drugs in Alzheimer's disease.5,6
Second-generation (atypical) antipsychotic drugs have been considered to be at least as effective as conventional antipsychotic agents such as haloperidol, with a lower risk of most adverse effects,7 and are used as first-line pharmacologic treatments for patients with dementia.5,8 However, there is a dearth of placebo-controlled and active-drug–controlled, randomized trials and longer-term data from controlled trials regarding the effectiveness of atypical antipsychotic drugs. Moreover, the available data on efficacy have been inconsistent, rates of response to placebo have been high, and patients have been required to receive drugs for the 6-week to 12-week study periods, whether or not they benefited, an artificial situation that does not address effectiveness.9
New safety issues have emerged with respect to atypical antipsychotic drugs. Increased risks of cerebrovascular adverse events10-12 and death13,14 have complicated their use. Antidepressant medications such as citalopram have been suggested as alternatives to antipsychotic drugs,15 at least for aggression or agitation,16 despite the lack of data from adequate trials.17
We conducted a double-blind, placebo-controlled trial to determine the effectiveness of olanzapine, quetiapine, and risperidone as compared with placebo in outpatients with Alzheimer's disease and psychosis, aggression, or agitation.
Methods
Study Setting and Design
The trial was part of the National Institute of Mental Health (NIMH) Clinical Antipsychotic Trials of Intervention Effectiveness. Such trials address broad outcomes in settings and with interventions that reflect usual practices. The rationale, design, and methods of this study — Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer's Disease (CATIE-AD) — have been described previously.18 The trial was conducted between April 2001 and November 2004 at 45 sites in the United States (26 university clinics, 7 Veterans Affairs medical centers, and 12 private-practice sites [3 sites did not randomly assign any patients]).
In phase 1 of the study, patients were randomly assigned under double-blind conditions to receive olanzapine, quetiapine, risperidone, or placebo in a 2:2:2:3 ratio. Doses were adjusted as clinically indicated by study physicians. If the physicians judged that the patient's response was not adequate at any time after the first 2 weeks, then treatment could be discontinued. Patients with an adequate response continued treatment for up to 36 weeks. Patients whose initial treatment was discontinued during phase 1 could be enrolled in phase 2 and randomly assigned under double-blind conditions to receive one of the antipsychotic drugs to which they were not initially assigned or to receive citalopram.18 This report is limited to phase 1 results.
Participants
Eligible participants fulfilled criteria for dementia of the Alzheimer's type (according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition)19 or probable Alzheimer's disease20 on the basis of the history, physical examination, results of structural brain imaging, and the score on the Mini–Mental State Examination (MMSE)21; the MMSE score had to be between 5 and 26 (on a scale from 0 to 30, with lower scores indicating poorer performance). To be eligible, patients had to be ambulatory and living at home or in an assisted-living facility. Eligible patients had delusions, hallucinations, aggression, or agitation that developed after the onset of dementia and was severe enough to disrupt their functioning and, in the opinion of the study physicians, to justify treatment with antipsychotic drugs. Signs and symptoms of psychosis, aggression, or agitation had to have occurred nearly daily during the previous week or at least intermittently for 4 weeks. During the week before they were randomly assigned to treatment, eligible patients also had a severity rating of at least “moderate” for conceptual disorganization, suspiciousness, or hallucinatory behavior on the Brief Psychiatric Rating Scale (BPRS).22 Alternatively, a frequency rating of “often” or “more frequently” and a severity rating of at least “moderate” were required for delusions, hallucinations, agitation, or “aberrant motor behavior” in the Neuropsychiatric Inventory.23 A study partner or caregiver who had regular contact with the patient was required to participate in the assessments.18
Patients were excluded if they had received a diagnosis of a primary psychotic disorder (e.g., schizophrenia), delirium, other dementia such as vascular dementia24 or Lewy-body dementia,25 or psychosis, agitation, or aggression that could be better accounted for by another medical condition, medication, or substance abuse. Patients were also excluded if they required psychiatric admission, were suicidal, were going to receive treatment with a cholinesterase inhibitor or antidepressant medication, had previously been treated with two of the three atypical antipsychotic drugs under study, or had contraindications to any of the study drugs.
The study was approved by the NIMH data and safety monitoring board and by the institutional review board at each site. Written informed consent was obtained from the patients or their legally authorized representatives and from the partners or caregivers who participated with the patients.
Interventions
The trial design encouraged prescribing that reflected clinical practice while maintaining the randomized and double-blind treatment assignment. The study physicians determined the starting doses and adjusted the doses on the basis of their clinical judgment and patients' responses. Medications were dispensed at each visit in the form of identically appearing small and large capsules containing lower and higher doses of olanzapine (Zyprexa, Eli Lilly; 2.5 mg or 5.0 mg), quetiapine (Seroquel, AstraZeneca; 25 mg or 50 mg), risperidone (Risperdal, Janssen Pharmaceutica; 0.5 mg or 1.0 mg), or placebo.
To treat difficult behaviors during the trial, study physicians could increase the dose of the study medication or prescribe a benzodiazepine or oral or parenteral haloperidol.
All patients and caregivers were given basic information about Alzheimer's disease.26 Caregivers were offered two counseling sessions during the first 18 weeks and could speak with staff members as needed.
Outcomes
The primary outcome measure was the time until discontinuation of treatment for any reason in phase 1. This outcome integrates the judgments of patients, caregivers, and clinicians regarding efficacy, safety, and tolerability into a global measure of effectiveness that reflects therapeutic benefits in relation to undesirable effects.
The two primary hypotheses in phase 1 were, first, there would be pairwise differences between the three groups given atypical antipsychotic agents and the placebo group in the time until discontinuation of treatment for any reason, and second, that among those antipsychotic drugs that were found to be different from placebo, none would be inferior to the others.
The main secondary outcome measure was the attainment of minimal or greater improvement on the Clinical Global Impression of Change (CGIC)27 scale at week 12 while the patients continued to receive the phase 1 drug. The other secondary outcomes were the time to the discontinuation of treatment in phase 1 because of lack of efficacy and the time to the discontinuation of treatment because of adverse events, intolerability, or death. Safety was assessed by eliciting information about the occurrence of adverse events. The patients' weight and prolactin, glucose, cholesterol, and triglyceride levels were measured at weeks 12, 24, and 36.
Statistical Analysis
Patients who underwent randomization and received at least one dose of the study medication were included in the intention-to-treat sample. Randomization was performed with the use of permuted blocks of nine per site without stratification and was implemented with the use of an interactive voice-response telephone system.
A total of 421 patients underwent randomization (from a target sample of 450 patients), yielding a statistical power of 99% to identify a difference of 33% in the rates of discontinuation of treatment by 36 weeks between any one of the drugs and placebo and a power of 80% to detect a difference of 20%, assuming a 60% rate of discontinuation in the placebo group.
We used Kaplan–Meier survival curves to estimate the time to the discontinuation of treatment for all patients in the intention-to-treat population. The treatment groups were compared with the use of Cox proportional-hazards regression models,28 stratified according to site. Sites with 17 or fewer patients were grouped according to the size and type of site (i.e., university clinic, private practice, or Veterans Affairs medical center) for a total of 15 sites (8 pooled and 7 with 18 or more randomly assigned patients).
In the Cox model, the overall difference among the treatment groups was evaluated with the use of a test with 3 degrees of freedom. If the difference was significant at a P value of less than 0.05, then each drug was compared with placebo by means of a Hochberg adjustment for multiple comparisons.29
Any antipsychotic drug found to be significantly better than placebo was then tested for noninferiority to the other antipsychotic agents. Noninferiority was concluded when the P value was less than 0.025 from a one-sided test with a margin of 2.0 (i.e., the upper limit of the 95% confidence interval [CI] for the hazard ratio was <2.0). Two atypical antipsychotic drugs were considered to be equivalent if the CI was contained within 0.5 and 2.0 (i.e., each drug was noninferior to the other); this was a broad equivalence margin for noninferiority.
Finally, any antipsychotic drug found to be noninferior to the other antipsychotic drugs was tested for superiority on the basis of a one-sided test with a P value of less than 0.025. Discontinuation of treatment for a specific reason was analyzed in the same way, except that the data for patients who discontinued treatment for a different reason were censored at the time of discontinuation.
Patients who had a response to the assigned study drug were defined as those who were still in phase 1 and who had a CGIC score indicating at least minimal improvement at 12 weeks; all patients who had discontinued medications or who did not have minimal improvement on the CGIC scale were classified as not having a response. Groups were compared with the use of a nonparametric analysis of covariance,30 stratified according to the type of site and adjusted for the following baseline covariates: age, sex, MMSE score, and total BPRS score. Statistical testing followed the same strategy as for time to discontinuation of treatment, with equivalence defined as a 95% CI of −0.20 to 0.20 for the difference between response rates.
The study was funded by the NIMH. The pharmaceutical companies whose drugs were included in the study donated drug supplies; they were not involved in the design of the study, analyses, or interpretation of results. The authors and a protocol committee (see the Appendix) designed the trial. The site investigators gathered the data, and one of the authors analyzed the data. The manuscript was written by the authors, who vouch for the completeness and veracity of the data and data analyses.
Results
Patients, Caregivers, and Medication Doses
A total of 521 patients were screened and 421 underwent randomization and received at least one dose of medication (Figure 1Figure 1
Enrollment and Outcomes.). Eighty-two percent of patients discontinued their initially assigned medication (i.e., during the 36-week follow-up period).Clinical characteristics of the patients are shown in Table 1Table 1
Baseline Characteristics of Patients Who Underwent Randomization.. Fifty-seven percent required a level of care equivalent to that given in assisted-living facilities, and 17% needed the equivalent of nursing home care.31 At baseline, 46% were receiving antihypertensive drugs, 24% cholesterol-lowering drugs, 16% antiinflammatory drugs, and 30% vitamin E.Fifty-two percent of caregivers were spouses, and 33% were children or sons-in-law or daughters-in-law. The mean ages of caregivers were 73.5 years for spouses and 51.2 years for children or their spouses; 71% were women.31 They spent a mean (±SD) of 5.2±4.0 hours per day in specific caregiving activities.32
The mean initially prescribed doses were 3.2 mg of olanzapine per day, 34.1 mg of quetiapine per day, and 0.7 mg of risperidone per day. The last prescribed mean dose in phase 1 was 5.5 mg of olanzapine per day, 56.5 mg of quetiapine per day, and 1.0 mg of risperidone per day. The mean number of capsules prescribed was similar for all treatment groups: 0.7 large or 1.4 small capsules per day initially, and 1.1 large or 2.2 small capsules per day for the last prescribed dose in phase 1.
Outcomes
There were no significant overall differences among treatment groups with regard to the time to discontinuation of treatment for any reason (Table 2Table 2
Medication Doses and Outcomes in the Intention-to-Treat Sample. and Figure 2AFigure 2Discontinuation of Treatment in Phase 1 According to Study Group.). The median time to discontinuation of treatment ranged from 5.3 weeks with quetiapine to 8.1 weeks with olanzapine.The median time to discontinuation of treatment because of lack of efficacy was longer in the olanzapine group (22.1 weeks) and the risperidone group (26.7 weeks) than in the placebo group (9.0 weeks) (Table 2 and Figure 2B). The hazard ratio for the discontinuation of treatment because of lack of efficacy was 0.51 (P<0.001) for olanzapine as compared with placebo, and 0.61 (P=0.01) for risperidone. The time to discontinuation of treatment with quetiapine owing to lack of efficacy (median, 9.1 weeks) did not differ significantly from that for placebo. For the discontinuation of treatment, olanzapine and risperidone were equivalent to each other (hazard ratio, 0.84; 95% CI, 0.53 to 1.32), and olanzapine was significantly superior to quetiapine (hazard ratio, 0.63; 95% CI, 0.41 to 0.96; P=0.02).
The time to discontinuation of treatment owing to intolerance of the study drug, adverse effects, or death favored placebo, with discontinuation rates of 24% for patients who received olanzapine, 16% for patients who received quetiapine, and 18% for patients who received risperidone, as compared with 5% for patients who received placebo (Table 2 and Figure 2C). All three groups of patients who received an atypical antipsychotic drug were significantly more likely to discontinue treatment than were those who received placebo (hazard ratio for olanzapine, 4.32; 95% CI, 1.84 to 10.12; for quetiapine, 3.58; 95% CI, 1.44 to 8.91; and for risperidone, 3.62; 95% CI, 1.45 to 9.04).
At 12 weeks, 32% of patients in the olanzapine group had a response (i.e., a CGIC score indicating at least minimal improvement with continued use of the phase 1 study medication), as compared with 26% in the quetiapine group, 29% in the risperidone group, and 21% in the placebo group; these rates were not significantly different (P=0.22). The overall rate of discontinuation of treatment at 12 weeks was 63%.
Adverse Events
There were no significant differences among the groups with regard to the proportion of patients who had at least one serious adverse event and the proportion who had any adverse event (Table 3Table 3
Adverse Events and Other Safety Outcomes in Phase 1.). There were higher rates of parkinsonism or extrapyramidal signs in the olanzapine and risperidone groups (12% in each) than in the quetiapine group (2%) or the placebo group (1%). Correspondingly, the proportion of patients with a score of 1 or more on the Simpson–Angus scale (on a scale of 0 to 4, with 1 indicating mild extrapyramidal signs, and 4 the most severe signs) was higher with olanzapine (14%) and risperidone (11%) than with placebo (2%).Sedation occurred more commonly with the three drugs (reported in 15 to 24% of patients) than with placebo (5%), and confusion or changes in mental status occurred more commonly with olanzapine (18%) and risperidone (11%) than with placebo (5%). Both cognitive disturbances and psychotic symptoms were more common with olanzapine (5% and 7%, respectively) than with the other medications or placebo (0 to 2%).
The body weight and body-mass index (BMI) of patients increased with antipsychotic drugs (by 0.4 to 1.0 lb [0.18 to 0.45 kg] per month and 0.2 BMI unit) and decreased slightly with placebo (by −0.9 lb [0.41 kg] per month and −0.2 BMI unit). Prolactin levels at week 12 were markedly elevated in the risperidone group only.
Ten patients entered nursing homes during phase 1 (two patients receiving olanzapine, four patients receiving quetiapine, three patients receiving risperidone, and one patient receiving placebo).
Discussion
In this study, we randomly assigned patients with Alzheimer's disease and psychosis, aggression, or agitation to placebo or one of three atypical antipsychotic medications. The median time to discontinuation of treatment for any reason ranged from 5 to 8 weeks, with no significant differences among the four groups. The study physicians discontinued the study drugs within 8 weeks after the start of treatment in about half the patients. This practice was consistent with the opinions of expert clinicians who have recommended discontinuing or switching antipsychotic treatment after 2 to 4 weeks in patients who are not benefiting from it.5,8 The time to discontinuation of treatment, due to lack of efficacy, favored olanzapine and risperidone but was offset by the increased rates of discontinuation of these drugs due to adverse events. Because the study was designed to allow patients who discontinued a study medication in phase 1 to enter phase 2 and be randomly assigned to a different study drug, expectations that the phase 2 treatments might be more effective may have increased the likelihood of earlier discontinuation of treatment during phase 1.
The study physicians increased the initial medication doses from an average of 1.4 small capsules to an average of 2.2, equivalent to approximately 1.0 mg of risperidone, 5.5 mg of olanzapine, and 57.0 mg of quetiapine. The risperidone and olanzapine doses were both within the ranges recommended by experts5 and used in previous trials.9 The quetiapine dose, however, was half to a quarter that used in two nursing home trials.9
The protocol committee was unwilling to use a higher minimum starting dose of quetiapine or a larger incremental dose because of the possibility of excess sedation, but the committee expected that physicians would determine dosing individually for each patient. The rates of adverse events were similar among the drugs, however, so the apparent reluctance to increase the dose may have been related to observed adverse events or concern that adverse events would occur with higher doses of risperidone or olanzapine. Nevertheless, the decision not to increase the dose in the face of an inadequate response limits some conclusions about efficacy and adverse effects.
Sedation was more likely with all of the anti-psychotic drugs than with placebo and was particularly likely with olanzapine, which was also associated with increased confusion. Although worsening of cognition has been observed in other trials of antipsychotic medications for the treatment of dementia,9 MMSE scores did not worsen in our trial. Extrapyramidal signs and symptoms with both risperidone and olanzapine were common reasons for the discontinuation of treatment. The clinical significance of the expected hyperprolactinemia with risperidone is uncertain. Patients gained weight with olanzapine and risperidone and lost weight with placebo; the possibility that antipsychotic drugs cause the metabolic syndrome in the elderly requires further investigation.
The key enrollment criterion — the physician's assessment that an antipsychotic drug was the appropriate pharmacologic therapy — helped to ensure clinical equipoise. The patient population was broad and representative in terms of age, race, ethnic group, level of disability, and extent of cognitive impairment. The level of psychopathology was moderate to severe, which is similar to that in studies of patients in nursing homes.Approximately 75% of the patients required a level of care at least equivalent to that given in assisted-living facilities.31 Most of the patients in our study required a level of care equivalent to that given in an assisted-living facility, and 17% needed the equivalent of nursing home care.31 Washout from previous treatment and run-in periods were not used because of the patients' acute clinical symptoms; instead, the study design allowed for rapid assignment and initiation of treatment to be consistent with clinical practice. Specifically, 14% percent of the patients were receiving antipsychotic medications within 2 weeks before randomization (5% risperidone, 4% haloperidol, 3% quetiapine, and 2% olanzapine). The use of cholinesterase inhibitors did not influence outcomes.
We used the discontinuation of treatment for any reason as a pragmatic measure of outcomes for individual patients rather than means for scores on rating scales because the discontinuation of treatment incorporates the judgments of patients, caregivers, and clinicians regarding efficacy, safety, and tolerability and reflects therapeutic benefits in relation to undesirable effects. Previous trials compared mean scores on rating scales according to group at the end of 6 to 12 weeks without regard to tolerability and did not address the outcomes among individual patients. Our results are consistent with those of the few previous outpatient trials of atypical antipsychotic medications,9 which showed modest trends or no significant effects on symptom ratings.
Overall, the rates of discontinuation of treatment among the four study groups ranged from 77 to 85%. Although the differences among the groups may have been significant in a larger trial, our findings suggest that there is no large clinical benefit of treatment with atypical antipsychotic medications as compared with placebo.
Physicians were likely to switch medications quickly in the face of lack of efficacy or adverse effects. Although the atypical antipsychotic drugs were more effective than placebo, adverse effects limited their overall effectiveness, and their use may be restricted to patients who have few or no side effects and for whom benefits can be discerned. Clinicians, patients, and family members must consider both risks and benefits in order to optimize a patient's care.
Supported by a grant (NO1 MH9001) from the NIMH. AstraZeneca Pharmaceuticals, Forest Pharmaceuticals, Janssen Pharmaceutica, and Eli Lilly provided medications for the studies.
Dr. Schneider reports having received consulting fees from AstraZeneca, Forest Laboratories, Johnson & Johnson, and Pfizer, and lecture fees from AstraZeneca, Eli Lilly, and Forest Laboratories; Dr. Tariot, consulting fees from GlaxoSmithKline and Novartis, consulting fees and research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Eisai, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly, Merck, Pfizer, and Schwabe, educational fees from AstraZeneca, Eisai, Forest Laboratories, Lundbeck, Merz, and Pfizer, and research support from Wyeth; Dr. Ismail, consulting and lecture fees from Forest Laboratories and Janssen Pharmaceutica; Dr. Lyketsos, research funding and educational fees from GlaxoSmithKline, consulting or advisory-board fees from Eisai, Forest Laboratories, and GlaxoSmithKline, and lecture fees from Pfizer, Forest Laboratories, and Novartis; Dr. Stroup, consulting fees from Janssen Pharmaceutica, Eli Lilly, and Pfizer and lecture fees from Eli Lilly and Pfizer; Dr. Sultzer, research funding from Forest Laboratories and Pfizer, consulting fees from Eli Lilly and Novartis, and lecture fees from AstraZeneca, Bristol-Myers Squibb, Pfizer, and Forest Laboratories; Dr. Weintraub, research funding from Forest Laboratories, consulting fees from Avanir Pharmaceuticals, Boehringer Ingelheim, Teva Pharmaceuticals, and GlaxoSmithKline, and lecture fees from AstraZeneca; and Dr. Lieberman, research funding from Acadia, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, and Pfizer. Dr. Davis reports having received consulting fees from Eli Lilly and Pfizer and being employed by Quintiles; Dr. Hsiao reports being employed by the NIMH; Dr. Lebowitz reports being formerly employed by the NIMH. Dr. Ryan reports having received lecture fees from Abbott, Forest Laboratories, AstraZeneca, Bristol-Myers Squibb, Eisai, Janssen Pharmaceutica, Pfizer, and research contracts from Johnson & Johnson and Eli Lilly, and being employed by Merck. No other potential conflict of interest relevant to this article was reported.
Source Information
From the Keck School of Medicine, University of Southern California, Los Angeles (L.S.S., K.S.D.); the Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Quintiles, Research Triangle Park, NC (S.M.D.); the National Institute of Mental Health, National Institutes of Health, Bethesda, MD (J.K.H.); the University of Rochester Medical Center, Rochester, NY (M.S.I., J.M.R.); the School of Medicine, University of California, San Diego, La Jolla (B.D.L.); the Department of Psychiatry, Johns Hopkins Bayview, Johns Hopkins University, Baltimore (C.G.L.); the School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (T.S.S.); Veterans Affairs Greater Los Angeles Healthcare System, University of California, Los Angeles, Los Angeles (D.L.S.); the School of Medicine, University of Pennsylvania, Philadelphia (D.W.); and the College of Physicians and Surgeons, New York (J.A.L.).
Address reprint requests to Dr. Schneider at the Keck School of Medicine, University of Southern California, 1510 San Pablo St., HCC 600, Los Angeles, CA 90033, or at lschneid@usc.edu.
Members of the Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer's Disease (CATIE-AD) Study Group are listed in the Appendix.
Appendix
The CATIE–AD Study Group includes the following members: Advisors and protocol committee — G. Alexopoulos, C.E. Davis, K.L. Davis, S. Davis, J.K. Hsiao, D.V. Jeste, I.R. Katz, K.R. Krishnan, G. Koch, B. Lebowitz, J.A. Lieberman, C.G. Lyketsos, D. Marin, B.G. Pollock, P.V. Rabins, R.A. Rosenheck, M. Sano, S. Schultz, G.W. Small, D. Sultzer; Trial center — K. Dagerman, M.S. Ismail, L.S. Schneider, P.N. Tariot; NIMH staff — J. Baum, B. Bowers, D. Eskenazi, P. Gibbons, J. Gonzalez, W.R. Harlan, J.K. Hsiao, S. Hyman, T. Insel, B.D. Lebowitz, G.S. Norquist, J.T. Olin, L. Ritz, J.B. Severe; University of North Carolina (UNC), Chapel Hill, and Duke University, Durham, NC — J.A. Lieberman (formerly at UNC, currently at Columbia University) and C.E. Davis (principal investigators); R. Keefe (Duke University), I. Rojas, S. Stroup (University of North Carolina at Chapel Hill), M. Swartz (Duke University); Quintiles — S. Abbott, P.J. Butler, M. DiJohn, J. Ho, B. LaPlante, I. Amara, S. Davis, S. Kavanagh; Study investigators — L. Adler, Clinical Insights, Baltimore; I. Ahmed, University of Hawaii, Honolulu; P. Aupperle, University of Medicine and Dentistry of New Jersey, Piscataway; S. Bartels, Dartmouth–Hitchcock Medical Center, Lebanon, NH; A. Baskys, Veterans Affairs Medical Center, Long Beach, CA; J. Beyer and M. Doraiswamy, Duke University Medical Center, Durham, NC; L. Blake, Northwestern University Medical School, Chicago; C.T. Cohen, SUNY Brooklyn, Brooklyn, NY; S. Colon, Veterans Affairs Medical Center, Tuscaloosa, AL; D. Devanand, Columbia University, New York; M. Dysken, Veterans Affairs Medical Center, Minneapolis; A. Freeman III, Louisiana State University Health Sciences Center, Shreveport; G.T. Grossberg, Saint Louis University, St. Louis; H. Grossman, Mount Sinai School of Medicine, New York; S. Gupta, Global Research and Consulting, Olean, NY; G. Haefner, Berman Research Group, Hialeah, FL; D. Jeste, University of California San Diego and Veterans Affairs Medical Center, San Diego; B. Jones and D. Johnston, Wake Forest University, Winston-Salem, NC; I. Katz and D. Weintraub, University of Pennsylvania and Veterans Affairs Medical Center, Coatesville; Z. Lebedeva and M. Parsa, Northeast Ohio Health Center, Columbus; M.T. Levy, Staten Island University Hospital, Staten Island, NY; C.G. Lyketsos, Johns Hopkins University, Baltimore; D. McManus, Southern Illinois University, Springfield; J.E. Mintzer, Medical University of South Carolina, North Charleston; R. Ownby, University of Miami, Miami; E. Palmer, Lahey Clinic, Burlington, MA; E. Pfeiffer, University of South Florida Suncoast Gerontology Center, Tampa; N. Pomara, Nathan S. Kline Institute, Orangeburg, NY; S. Potkin, University of California Irvine, Irvine; J.M. Ryan, Monroe Community Hospital, Rochester, NY; C. Sadowsky, Palm Beach Neurology, West Palm Beach, FL; B. Saltz, Mental Health Advocates, Boca Raton, FL; S. Scheinthal, University of Medicine and Dentistry of New Jersey, Stratford; L.S. Schneider and S. Pawluczyk, University of Southern California, Los Angeles; S. Schultz, University of Iowa College of Medicine, Iowa City; J. Sheikh, Stanford University School of Medicine, Stanford, CA; F. Sicuro, Millennium Psychiatric Associates, St. Louis; P. Solomon, Southwestern Vermont Medical Center, Bennington; D. Sultzer, Veterans Affairs Greater Los Angeles Healthcare System, University of California, Los Angeles, Los Angeles; L. Tune, Wesley Woods Health Center, Atlanta; C.H. van Dyck, Yale University School of Medicine, New Haven, CT; M. Weiner, University of Texas Southwestern Medical Center, Dallas.
- References
References
1
Tariot PN ,Schneider LS ,Katz IR . Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. J Geriatr Psychiatry Neurol 1995;8:Suppl 1:S28-S39
CrossRef | Web of Science | Medline2
Devanand DP ,Jacobs DM ,Tang MX , et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997;54:257-263
Web of Science | Medline3
Jeste DV ,Finkel SI . Psychosis of Alzheimer's disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000;8:29-34
CrossRef | Web of Science | Medline4
Paulsen JS ,Salmon DP ,Thal LJ , et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000;54:1965-1971
Web of Science | Medline5
Alexopoulos GS ,Streim J ,Carpenter D ,Docherty JP . Using antipsychotic agents in older patients. J Clin Psychiatry 2004;65:Suppl 2:5-104
Web of Science | Medline6
Schneider LS ,Pollock VE ,Lyness SA . A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38:553-563
Web of Science | Medline7
Jeste DV ,Lacro JP ,Bailey A ,Rockwell E ,Harris MJ ,Caligiuri MP . Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-719
Web of Science | Medline8
Alexopoulos GS ,Silver JM ,Kahn DA ,Frances A ,Carpenter D . Treatment of agitation in older persons with dementia. Postgrad Med 1998;Special No.:1-88. Alexopoulos GS, Silver JM, Kahn DA, Frances A, Carpenter D. Treatment of agitation in older persons with dementia. Postgrad Med 1998;Special No.:1-88.;9
Schneider LS ,Dagerman K ,Insel PS . Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210
CrossRef | Web of Science | Medline10
Wooltorton E . Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269-1270
Web of Science | Medline11
Wooltorton E . Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170:1395-1395
CrossRef | Web of Science | Medline12
Racoosin JA. Evaluating a safety signal in the postmarking period: cerebrovascular adverse events associated with risperidone and olanzapine. Presented at the 17th Annual Meeting of the American Association for Geriatric Psychiatry, Baltimore, February 21–24, 2004 (paper).
13
Schneider LS ,Dagerman KS ,Insel P . Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943
CrossRef | Web of Science | Medline14
Center for Drug Evaluation and Research. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. April 11, 2005. (Accessed September 15, 2006, at http://www.fda.gov/cder/drug/advisory/antipsychotics.htm.)
15
Lyketsos CG ,Olin J . Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry 2002;52:243-252
CrossRef | Web of Science | Medline16
Pollock BG ,Mulsant BH ,Rosen J , et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002;159:460-465
CrossRef | Web of Science | Medline17
Olin JT ,Katz IR ,Meyers BS ,Schneider LS ,Lebowitz BD . Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry 2002;10:129-141
Web of Science | Medline18
Schneider LS ,Tariot PN ,Lyketsos CG , et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 2001;9:346-360
CrossRef | Web of Science | Medline19
Dementia of the Alzheimer's type. In: Diagnostic and statistical manual of mental disorders. 4th ed. text revision: DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000:154-8.
20
McKhann G ,Drachman D ,Folstein M ,Katzman R ,Price D ,Stadlan EM . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944
Web of Science | Medline21
Folstein MF ,Folstein SE ,McHugh PR . “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
CrossRef | Web of Science | Medline22
Beller SA ,Overall JE . The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research. II. Representative profile patterns. J Gerontol 1984;39:194-200
Medline23
Cummings JL ,Mega M ,Gray K ,Rosenberg-Thompson S ,Carusi DA ,Gornbein J . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314
Web of Science | Medline24
Roman GC ,Tatemichi TK ,Erkinjuntti T , et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260
Web of Science | Medline25
McKeith IG ,Galasko D ,Kosaka K , et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology 1996;47:1113-1124
Web of Science | Medline26
Mittelman MS, Bergman H, Shulman E, Steinberg G, Epstein C. Guiding the Alzheimer's Caregiver: a handbook for counselors. New York: New York University School of Medicine, 2000.
27
Schneider LS ,Olin JT ,Doody RS , et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:Suppl 2:S22-S32
CrossRef | Web of Science | Medline28
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22029
Hochberg Y . A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-802
CrossRef | Web of Science30
Koch GG ,Tangen CM ,Jung JW ,Amara IA . Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Stat Med 1998;17:1863-1892
CrossRef | Web of Science | Medline31
Ismail MS, Dagerman K, Tariot PN, Abbott S, Kavanaugh S, Schneider LS. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD): baseline characteristics. Curr Alzheimer Res (in press).
32
Davis KL ,Marin DB ,Kane R , et al. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:978-988
CrossRef | Web of Science | Medline33
Agresti A. Categorical data analysis. New York: John Wiley, 1990.
34
21 C.F.R. § 312.32 (revised as of April 1, 2006).
- Citing Articles (256)
Citing Articles
1
Malaz A. Boustani, Noll L. Campbell, Babar A. Khan, Greg Abernathy, Mohammed Zawahiri, Tiffany Campbell, Jason Tricker, Siu L. Hui, John D. Buckley, Anthony J. Perkins, Mark O. Farber, Christopher M. Callahan. (2012) Enhancing Care for Hospitalized Older Adults with Cognitive Impairment: A Randomized Controlled Trial. Journal of General Internal Medicine
CrossRef2
Yeonsu Song, Lorena Jung, Kathy C Richards. (2012) Dementia and sleep disturbances. Aging Health 8:1, 65-78
CrossRef3
Lea T. Drye, Zahinoor Ismail, Anton P. Porsteinsson, Paul B. Rosenberg, Daniel Weintraub, Christopher Marano, Gregory Pelton, Constantine Frangakis, Peter V. Rabins, Cynthia A. Munro, Curtis L. Meinert, D.P. Devanand, Jerome Yesavage, Jacobo E. Mintzer, Lon S. Schneider, Bruce G. Pollock, Constantine G. Lyketsos. (2012) Citalopram for agitation in Alzheimer’s disease: Design and methods. Alzheimer's and Dementia
CrossRef4
Dustin M. Hipp, E. Wesley Ely. (2012) Pharmacological and Nonpharmacological Management of Delirium in Critically Ill Patients. Neurotherapeutics
CrossRef5
J. Loretta Mulcare, Stephen E. Nicolson, Viwek S. Bisen, Samuel O. Sostre. (2012) The Mirror Sign: A Reflection of Cognitive Decline?. Psychosomatics
CrossRef6
Yves Rolland, Sandrine Andrieu, Anne Crochard, Sylvia Goni, Christophe Hein, Bruno Vellas. (2012) Psychotropic Drug Consumption at Admission and Discharge of Nursing Home Residents. Journal of the American Medical Directors Association
CrossRef7
Jennifer Tjia, Jerry H. Gurwitz, Becky A. Briesacher. (2012) Challenge of Changing Nursing Home Prescribing Culture. The American Journal of Geriatric Pharmacotherapy
CrossRef8
Carlotta Franchi, Mauro Tettamanti, Alessandra Marengoni, Francesca Bonometti, Luca Pasina, Laura Cortesi, Ida Fortino, Angela Bortolotti, Luca Merlino, Ugo Lucca, Emma Riva, Alessandro Nobili. (2012) Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. European Neuropsychopharmacology
CrossRef9
I. C. V. Thuné-Boyle, S. Iliffe, A. Cerga-Pashoja, D. Lowery, J. Warner. (2011) The effect of exercise on behavioral and psychological symptoms of dementia: towards a research agenda. International Psychogeriatrics1-12
CrossRef10
Howard S. Kirshner. (2011) Efficacy and Safety of Antidepressant Drugs in Patients with Dementia. Current Neurology and Neuroscience Reports 11:6, 520-522
CrossRef11
Marja-Liisa Laitinen, J. Simon Bell, Piia Lavikainen, Eija Lönnroos, Raimo Sulkava, Sirpa Hartikainen. (2011) Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer's disease in Finland. International Psychogeriatrics 23:10, 1623-1631
CrossRef12
Sytse U. Zuidema, Jos F. M. de Jonghe, Frans R. J. Verhey, Raymond T. C. M. Koopmans. (2011) Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians’ prescription behavior. International Psychogeriatrics 23:10, 1632-1639
CrossRef13
Hugo Lövheim, Yngve Gustafson, Stig Karlsson, Per-Olof Sandman. (2011) Comparison of behavioral and psychological symptoms of dementia and psychotropic drug treatments among old people in geriatric care in 2000 and 2007. International Psychogeriatrics 23:10, 1616-1622
CrossRef14
Stephen Vida, Johanne Monette, Machelle Wilchesky, Michèle Monette, Ruby Friedman, Anh Nguyen, Dolly Dastoor, Gabriela Cristache, Nadia Sourial, Lucie Tremblay, Brian Gore. (2011) A long-term care center interdisciplinary education program for antipsychotic use in dementia: program update five years later. International Psychogeriatrics1-7
CrossRef15
Cheryl M. Bradas, Lorraine C. Mion. (2011) Hospitalized Patients with Dementia: The Dilemma of Managing Agitation. Geriatric Nursing
CrossRef16
Yoram Barak, Igor Plopski, Shelly Tadger, Diana Paleacu. (2011) Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. International Psychogeriatrics 23:09, 1515-1519
CrossRef17
Alan M. Mandell, Robert C. Green. 2011. Alzheimer's Disease. , 1-91.
CrossRef18
Christopher I. Wright. 2011. Emotion and Behavior in Alzheimer's Disease and Other Dementias. , 416-456.
CrossRef19
B.S. Husebo, C. Ballard, D. Aarsland. (2011) Pain treatment of agitation in patients with dementia: a systematic review. International Journal of Geriatric Psychiatry 26:10, 1012-1018
CrossRef20
Jennifer M. Polinski, Julie M. Donohue, Elaine Kilabuk, William H. Shrank. (2011) Medicare Part D's Effect on the Under- and Overuse of Medications: A Systematic Review. Journal of the American Geriatrics Society 59:10, 1922-1933
CrossRef21
Franciska Desplenter, Charlotte Caenen, Jolein Meelberghs, Sirpa Hartikainen, Raimo Sulkava, J. Simon Bell. (2011) Change in psychotropic drug use among community-dwelling people aged 75 years and older in Finland: repeated cross-sectional population studies. International Psychogeriatrics 23:08, 1278-1284
CrossRef22
Gabriele Cipriani, Marcella Vedovello, Angelo Nuti, Mario Di Fiorino. (2011) Aggressive behavior in patients with dementia: Correlates and management. Geriatrics & Gerontology International 11:4, 408-413
CrossRef23
Constantine G. Lyketsos, Maria C. Carrillo, J. Michael Ryan, Ara S. Khachaturian, Paula Trzepacz, Joan Amatniek, Jesse Cedarbaum, Robert Brashear, David S. Miller. (2011) Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimer's and Dementia 7:5, 532-539
CrossRef24
Christian R. Dolder, Jonathan Mckinsey. (2011) Antipsychotic Polypharmacy Among Patients Admitted to a Geriatric Psychiatry Unit. Journal of Psychiatric Practice 17:5, 368-374
CrossRef25
YongJoo Rhee, John G. Csernansky, Linda L. Emanuel, Chang-Gok Chang, Joseph W. Shega. (2011) Psychotropic Medication Burden and Factors Associated with Antipsychotic Use: An Analysis of a Population-Based Sample of Community-Dwelling Older Persons with Dementia. Journal of the American Geriatrics Societyn/a-n/a
CrossRef26
D.P. Devanand, Gregory H. Pelton, Karine Cunqueiro, Harold A. Sackeim, Karen Marder. (2011) A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. International Journal of Geriatric Psychiatry 26:9, 937-943
CrossRef27
Brendon Stubbs, Lee Hollins. (2011) Are physical intervention techniques likely to cause pain or injury when applied to manage the severely aggressive older adult? A survey of physiotherapist’s expert views in the UK. Journal of Clinical Nursing 20:17-18, 2666-2675
CrossRef28
J. E. Morley. (2011) Can we improve care for patients with dementia?. The journal of nutrition, health & aging 15:7, 523-526
CrossRef29
Anirban Basu, Anupam B. Jena, Tomas J. Philipson. (2011) The impact of comparative effectiveness research on health and health care spending. Journal of Health Economics 30:4, 695-706
CrossRef30
A. Scheifes, J. J. Stolker, A. C. G. Egberts, H. L. I. Nijman, E. R. Heerdink. (2011) Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems. Journal of Intellectual Disability Research 55:7, 650-664
CrossRef31
Nicole Pratt, Elizabeth E. Roughead, Emmae Ramsay, Amy Salter, Philip Ryan. (2011) Risk of Hospitalization for Hip Fracture and Pneumonia Associated with Antipsychotic Prescribing in the Elderly. Drug Safety 34:7, 567-575
CrossRef32
Ann Kolanowski, Mark Litaker, Lin Buettner, Joyel Moeller, Paul T. Costa Jr.. (2011) A Randomized Clinical Trial of Theory-Based Activities for the Behavioral Symptoms of Dementia in Nursing Home Residents. Journal of the American Geriatrics Society 59:6, 1032-1041
CrossRef33
Milap A. Nowrangi, Vani Rao, Constantine G. Lyketsos. (2011) Epidemiology, Assessment, and Treatment of Dementia. Psychiatric Clinics of North America 34:2, 275-294
CrossRef34
Jessica J. Jalbert, Lori A. Daiello, Charles B. Eaton, Susan C. Miller, Kate L. Lapane. (2011) Antipsychotic Use and the Risk of Diabetes in Nursing Home Residents with Dementia. The American Journal of Geriatric Pharmacotherapy 9:3, 153-163
CrossRef35
Yong Chen, Becky A. Briesacher. (2011) Use of instrumental variable in prescription drug research with observational data: a systematic review. Journal of Clinical Epidemiology 64:6, 687-700
CrossRef36
A. Larrayadieu, G. Abellan van Kan, A. Piau, M. Soto Martin, F. Nourhashemi, Y. Rolland, B. Vellas. (2011) Associated factors with antipsychotic use in assisted living facilities: a cross-sectional study of 4367 residents. Age and Ageing 40:3, 368-375
CrossRef37
Paul Howard, Robert Twycross, John Shuster, Mary Mihalyo, Andrew Wilcock. (2011) Antipsychotics. Journal of Pain and Symptom Management 41:5, 956-965
CrossRef38
Thomas W. Meeks, John W. Culberson, Monica S. Horton. (2011) Medications in Long-Term Care: When Less is More. Clinics in Geriatric Medicine 27:2, 171-191
CrossRef39
Debbie Tolson, John E. Morley. (2011) Medical Care in the Nursing Home. Medical Clinics of North America 95:3, 595-614
CrossRef40
Edward Alan Miller, Robert A. Rosenheck, Lon S. Schneider. (2011) Caregiver burden, health utilities, and institutional service use in Alzheimer's disease. International Journal of Geriatric Psychiatryn/a-n/a
CrossRef41
Freddi Segal-Gidan, Debra Cherry, Randi Jones, Bradley Williams, Linda Hewett, Joshua Chodosh. (2011) Alzheimer’s Disease Management Guideline: Update 2008. Alzheimer's and Dementia 7:3, e51-e59
CrossRef42
Jane E. Fisher. (2011) Understanding Behavioral Health in Late Life: Why Age Matters. Behavior Therapy 42:1, 143-149
CrossRef43
Carole Parsons, Kate Lapane, Ngaire Kerse, Carmel Hughes. (2011) Prescribing for older people in nursing homes: a review of the key issues. International Journal of Older People Nursing 6:1, 45-54
CrossRef44
Dallas P Seitz, Nikesh Adunuri, Sudeep S. Gill, Andrea Gruneir, Nathan Herrmann, Paula Rochon, Dallas P Seitz. 2011. Antidepressants for agitation and psychosis in dementia. .
CrossRef45
Ralf Ihl, Lutz Frölich, Bengt Winblad, Lon Schneider, Alistair Burns, Hans-Jürgen Möller. (2011) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias. World Journal of Biological Psychiatry 12:1, 2-32
CrossRef46
Edward Alan Miller, Lon S. Schneider, Robert A. Rosenheck. (2011) Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation. International Psychogeriatrics 23:01, 44-53
CrossRef47
Lothar Burghaus, Carsten Eggers, Lars Timmermann, Gereon R. Fink, Nico J. Diederich. (2011) Hallucinations in Neurodegenerative Diseases. CNS Neuroscience & Therapeuticsno-no
CrossRef48
Manjula Kurella Tamura, Kristine Yaffe. (2011) Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies. Kidney International 79:1, 14-22
CrossRef49
John E. Morley. (2011) Alzheimer’s Disease: Future Treatments. Journal of the American Medical Directors Association 12:1, 1-7
CrossRef50
Massimo Musicco, Katie Palmer, Antonio Russo, Carlo Caltagirone, Fulvio Adorni, Carla Pettenati, Luigi Bisanti. (2011) Association between Prescription of Conventional or Atypical Antipsychotic Drugs and Mortality in Older Persons with Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders 31:3, 218-224
CrossRef51
Pilar Hereu, Antonio Vallano. (2011) Uso de antipsicóticos en pacientes con demencia. Revista Española de Geriatría y Gerontología 46:1, 50-53
CrossRef52
David A. Merrill, David L. Sultzer. 2010. Behavioural Management in Alzheimer's Disease - Pharmacology. , 312-323.
CrossRef53
Peter M. Haddad, Venkata S. Mattay. 2010. Neurological Complications of Antipsychotic Drugs. , 561-576.
CrossRef54
Esther Cornegé-Blokland, Bart C. Kleijer, Cees M.P.M. Hertogh, Rob J. van Marum. (2010) Reasons to Prescribe Antipsychotics for the Behavioral Symptoms of Dementia: A Survey in Dutch Nursing Homes Among Physicians, Nurses, and Family Caregivers. Journal of the American Medical Directors Association
CrossRef55
David G. Stevenson, Sandra L. Decker, Lisa L. Dwyer, Haiden A. Huskamp, David C. Grabowski, Eran D. Metzger, Susan L. Mitchell. (2010) Antipsychotic and Benzodiazepine Use Among Nursing Home Residents. American Journal of Geriatric Psychiatry 18:12, 1078-1092
CrossRef56
Alette M. Wessels, Bruce G. Pollock, Norbert G. Anyama, Lon S. Schneider, Jeffrey A. Lieberman, Stephen R. Marder, Robert R. Bies. (2010) Association of 9-Hydroxy Risperidone Concentrations With Risk of Switching or Discontinuation in the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial. Journal of Clinical Psychopharmacology 30:6, 683-687
CrossRef57
Maha Saad, Manouchkathe Cassagnol, Ebtesam Ahmed. (2010) The Impact of FDA's Warning on the Use of Antipsychotics in Clinical Practice: A Survey. The Consultant Pharmacist 25:11, 739-744
CrossRef58
Douglas W. Scharre, Francis Vekeman, Patrick Lefebvre, Nikita Mody-Patel, Kristijan H. Kahler, Mei Sheng Duh. (2010) Use of Antipsychotic Drugs in Patients with Alzheimerʼs Disease Treated with Rivastigmine versus Donepezil. Drugs & Aging 27:11, 903-913
CrossRef59
Nicole L. Pratt, Elizabeth E. Roughead, Emmae Ramsay, Amy Salter, Philip Ryan. (2010) Risk of Hospitalization for Stroke Associated with Antipsychotic Use in the Elderly. Drugs & Aging 27:11, 885-893
CrossRef60
Roland Wetzels, Sytse Zuidema, Iepke Jansen, Frans Verhey, Raymond Koopmans. (2010) Course of neuropsychiatric symptoms in residents with dementia in long-term care institutions: a systematic review. International Psychogeriatrics 22:07, 1040-1053
CrossRef61
Christian R. Dolder, Jonathan McKinsey. (2010) Quetiapine for Sleep in Patients with Dementia. The Consultant Pharmacist 25:10, 676-679
CrossRef62
RJ van Marum. (2010) Antipsychotic drug use and the risk of developing pneumonia. Aging Health 6:5, 529-532
CrossRef63
Salvatore Gentile. (2010) Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology 212:2, 119-129
CrossRef64
Somaia Mohamed, Robert Rosenheck, Constantine G. Lyketsos, Lon S. Schneider. (2010) Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates. American Journal of Geriatric Psychiatry 18:10, 917-927
CrossRef65
G. B. Rattinger, C. D. Mullins, I. H. Zuckerman, E. Onukwugha, S. Delisle. (2010) Clinic visits and prescribing patterns among veterans affairs maryland health care system dementia patients. The journal of nutrition, health & aging 14:8, 677-683
CrossRef66
Bart C. Kleijer, Rob J. Marum, A.C.G. (Toine) Egberts, Paul A.F. Jansen, Dinnus H.M. Frijters, E.R. (Rob) Heerdink, Miel W. Ribbe. (2010) Het beloop van gedragsproblemen bij oudere verpleeghuispatiënten met dementie die worden behandeld met antipsychotica. Tijdschrift voor ouderengeneeskunde
CrossRef67
Kyoung Bin Im, Scott Strader, Mark Eric Dyken. (2010) Management of Sleep Disorders in Stroke. Current Treatment Options in Neurology 12:5, 379-395
CrossRef68
Paul T. Francis, María J. Ramírez, Mitchell K. Lai. (2010) Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 59:4-5, 221-229
CrossRef69
Tanja Richter, Gabriele Meyer, Sascha Köpke, Sascha Köpke. 2010. Psychosocial interventions for reducing antipsychotic medication in care home residents. .
CrossRef70
J. E. Morley. (2010) Clinical practice in nursing homes as a key for progress. The journal of nutrition, health & aging 14:7, 586-593
CrossRef71
Laura N. Gitlin, Laraine Winter, Marie P. Dennis, Nancy Hodgson, Walter W. Hauck. (2010) Targeting and Managing Behavioral Symptoms in Individuals with Dementia: A Randomized Trial of a Nonpharmacological Intervention. Journal of the American Geriatrics Society 58:8, 1465-1474
CrossRef72
Michael Bird, Annaliese Blair. (2010) Clinical Psychology and anxiety and depression in dementia. Nordic Psychology 62:2, 44-54
CrossRef73
Nicole Pratt, Elizabeth E. Roughead, Philip Ryan, Amy Salter. (2010) Antipsychotics and the risk of death in the elderly: an instrumental variable analysis using two preference based instruments. Pharmacoepidemiology and Drug Safety 19:7, 699-707
CrossRef74
Giacomo Chiabrando, Stefano Bianchi, Elisabetta Poluzzi, Nicola Montanaro, Paola Scanavacca. (2010) Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. European Journal of Clinical Pharmacology 66:7, 661-669
CrossRef75
I. Testad, S. Auer, M. Mittelman, C. Ballard, J. Fossey, Y. Donabauer, D. Aarsland. (2010) Nursing home structure and association with agitation and use of psychotropic drugs in nursing home residents in three countries: Norway, Austria and England. International Journal of Geriatric Psychiatry 25:7, 725-731
CrossRef76
Mayeux, Richard, . (2010) Early Alzheimer's Disease. New England Journal of Medicine 362:23, 2194-2201
Full Text77
Rebecca C. Rossom, Thomas S. Rector, Frank A. Lederle, Maurice W. Dysken. (2010) Are All Commonly Prescribed Antipsychotics Associated with Greater Mortality in Elderly Male Veterans with Dementia?. Journal of the American Geriatrics Society 58:6, 1027-1034
CrossRef78
Carole Parsons, Carmel M. Hughes, A. Peter Passmore, Kate L. Lapane. (2010) Withholding, Discontinuing and Withdrawing Medications in Dementia Patients at the End of Life. Drugs & Aging 27:6, 435-449
CrossRef79
Juanita Westbury, Karin Beld, Shane Jackson, Gregory Peterson. (2010) Review of psychotropic medication in Tasmanian residential aged care facilities. Australasian Journal on Ageing 29:2, 72-76
CrossRef80
C. Rummel-Kluge, K. Komossa, S. Schwarz, H. Hunger, F. Schmid, W. Kissling, J. M. Davis, S. Leucht. (2010) Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons. Schizophrenia Bulletin
CrossRef81
Jennifer Tjia, Margaret R. Rothman, Dan K. Kiely, Michele L. Shaffer, Holly M. Holmes, Greg A. Sachs, Susan L. Mitchell. (2010) Daily Medication Use in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society 58:5, 880-888
CrossRef82
Serge Gauthier, Jeffrey Cummings, Clive Ballard, Henry Brodaty, George Grossberg, Philippe Robert, Constantine Lyketsos. (2010) Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics 22:03, 346
CrossRef83
Prasad S. Nishtala, Andrew J. McLachlan, J. Simon Bell, Timothy F. Chen. (2010) Determinants of antipsychotic medication use among older people living in aged care homes in Australia. International Journal of Geriatric Psychiatry 25:5, 449-457
CrossRef84
P. Naarding, M. van Grevenstein, A. T. F. Beekman. (2010) Benefit-risk analysis for the clinician: ‘primum non nocere’ revisited-the case for antipsychotics in the treatment of behavioural disturbances in dementia. International Journal of Geriatric Psychiatry 25:5, 437-440
CrossRef85
G. Caleb Alexander. (2010) Clinical Prescribing (and Off-Label Use) in a Second-Best World. Medical Care 48:4, 285-287
CrossRef86
Emilio Sacchetti, Cesare Turrina, Paolo Valsecchi. (2010) Cerebrovascular Accidents in Elderly People Treated with Antipsychotic Drugs. Drug Safety 33:4, 273-288
CrossRef87
Karen Schendel Anderson, Pamela Bjorklund. (2010) Demystifying Federal Nursing Home Regulations to Improve the Effectiveness of Psychopharmacological Care. Perspectives in Psychiatric Care 46:2, 152-162
CrossRef88
Yoshihito Hayashi, Yasushi Ishida, Teruhiko Inoue, Mitsutaka Udagawa, Kouzou Takeuchi, Hirofumi Yoshimuta, Kouichirou Kiue, Yoshimasa Ninomiya, Jiro Kawano, Tetsuro Sameshima, Takashi Kawahara, Isamu Goto, Kenji Shudo, Shigeki Kurayama, Jungo Nakamura, Kazunori Okahara, Yoshio Mitsuyama. (2010) Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34:3, 541-545
CrossRef89
Jiska Cohen-Mansfield, Marcia S. Marx, Maha Dakheel-Ali, Natalie G. Regier, Khin Thein. (2010) Can Persons With Dementia Be Engaged With Stimuli?. American Journal of Geriatric Psychiatry 18:4, 351-362
CrossRef90
J. L. Westbury, S. Jackson, G. M. Peterson. (2010) Psycholeptic use in aged care homes in Tasmania, Australia. Journal of Clinical Pharmacy and Therapeutics 35:2, 189-193
CrossRef91
(2010) Aktuell. Psychopraxis 13:2, 36-41
CrossRef92
Samantha A. Hollingworth, Dan J. Siskind, Lisa M. Nissen, Maxine Robinson, Wayne D. Hall. (2010) Patterns of antipsychotic medication use in Australia 2002–2007. Australian and New Zealand Journal of Psychiatry 44:4, 372-377
CrossRef93
Javier Gómez-Pavón, Paloma González García, Inés Francés Román, Maite Vidán Astiz, José Gutiérrez Rodríguez, Gregorio Jiménez Díaz, Nuria Pilar Montero Fernández, Baldomero Álvarez Fernández, José María Jiménez Páez. (2010) Recomendaciones en la prevención de reacciones adversas a medicamentos en personas mayores con demencia. Revista Española de Geriatría y Gerontología 45:2, 89-96
CrossRef94
Michele C. Balas. (2010) Free your MIND and the rest will follow: Decoding delirium in the intensive care unit*. Critical Care Medicine 38:2, 697-698
CrossRef95
Constantine G. Lyketsos. (2010) The Interface Between Depression and Dementia: Where Are We With This Important Frontier?. American Journal of Geriatric Psychiatry 18:2, 95-97
CrossRef96
Christophe Arbus, Virginie Gardette, Eric Bui, Christelle Cantet, Sandrine Andrieu, Fati Nourhashémi, Laurent Schmitt, Bruno Vellas, . (2010) Antidepressant use in Alzheimer's disease patients: results of the REAL.FR cohort. International Psychogeriatrics 22:01, 120
CrossRef97
Isabel Fort, Francesc Formiga, María José Robles, Pedro Regalado, Daniel Rodríguez, Elena Barranco. (2010) Alta prevalencia de consumo de neurolépticos en las personas ancianas con demencia. Medicina Clínica 134:3, 101-106
CrossRef98
Dallas P Seitz, Nikesh Adunuri, Sudeep Gill, Andrea Gruneir, Nathan Herrmann, Paula Rochon, Dallas P Seitz. 2010. Antidepressants for agitation and psychosis in dementia. .
CrossRef99
Ian D Cameron, Geoff R Murray, Lesley D Gillespie, M Clare Robertson, Keith D Hill, Robert G Cumming, Ngaire Kerse, Ian D Cameron. 2010. Interventions for preventing falls in older people in nursing care facilities and hospitals. .
CrossRef100
J. Simon Bell, Heidi T. Taipale, Helena Soini, Kaisu H. Pitkälä. (2010) Sedative Load among Long-Term Care Facility Residents with and without Dementia. Clinical Drug Investigation 30:1, 63-70
CrossRef101
Bruno Millet, Jean-Marie Vanelle, Joseph Benyaya. 2010. Les psychotropes chez le sujet âgé. , 261-272.
CrossRef102
Alexandre Y. Dombrovski, Benoit H. Mulsant, Robert E. Ferrell, Francis E. Lotrich, Jules I. Rosen, Meredith Wallace, Patricia R. Houck, Sati Mazumdar, Bruce G. Pollock. (2010) Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. International Clinical Psychopharmacology 25:1, 37-45
CrossRef103
Champa Balalle, Dilini Jayalath, Kuttalingham Shankar, Kunle Ashaye. (2010) Prevalence and Management of Behavioural and Psychiatric Symptoms on a Continuing Care Unit for Patients with Dementia. The International Journal of Psychiatry in Medicine 40:4, 425-438
CrossRef104
Michael Makhinson. (2010) Biases in Medication Prescribing: The Case of Second-Generation Antipsychotics. Journal of Psychiatric Practice 16:1, 15-21
CrossRef105
Laura N. Gitlin, Nancy Hodgson, Eric Jutkowitz, Laura Pizzi. (2009) The Cost-Effectiveness of a Nonpharmacologic Intervention for Individuals With Dementia and Family Caregivers: The Tailored Activity Program. American Journal of Geriatric Psychiatry1
CrossRef106
Clive Ballard, Anne Corbett, Ramilgan Chitramohan, Das Aarsland. (2009) Management of agitation and aggression associated with Alzheimerʼs disease: controversies and possible solutions. Current Opinion in Psychiatry 22:6, 532-540
CrossRef107
&NA;. (2009) Few pharmacological options available for treating cognitive impairment associated with severe Alzheimerʼs disease. Drugs & Therapy Perspectives 25:10, 9-11
CrossRef108
B. C. Kleijer, R. J. van Marum, A. C. G. Egberts, P. A. F. Jansen, D. Frijters, E. R. Heerdink, M. Ribbe. (2009) The course of behavioral problems in elderly nursing home patients with dementia when treated with antipsychotics. International Psychogeriatrics 21:05, 931
CrossRef109
Pamela L. Lindsey. (2009) Psychotropic Medication Use Among Older Adults. Journal of Gerontological Nursing 35:9, 28-38
CrossRef110
Lucy Y. Wang, Jane B. Shofer, Kirsten Rohde, Kim L. Hart, David J. Hoff, Yun H. McFall, Murray A. Raskind, Elaine R. Peskind. (2009) Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression. American Journal of Geriatric Psychiatry 17:9, 744-751
CrossRef111
Susan E. Bronskill, Paula A. Rochon, Sudeep S. Gill, Nathan Herrmann, Michael P. Hillmer, Chaim M. Bell, Geoffrey M. Anderson, Thérèse A. Stukel. (2009) The Relationship Between Variations in Antipsychotic Prescribing Across Nursing Homes and Short-Term Mortality. Medical Care 47:9, 1000-1008
CrossRef112
Clive Ballard, Richard Brown, Jane Fossey, Simon Douglas, Paul Bradley, Judith Hancock, Ian A. James, Edmund Juszczak, Peter Bentham, Alistair Burns, James Lindesay, Robin Jacoby, John O’Brien, Roger Bullock, Tony Johnson, Clive Holmes, Robert Howard. (2009) Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial). American Journal of Geriatric Psychiatry 17:9, 726-733
CrossRef113
M. Benoît, E. Camus, X. Cnockaert, F. Nourashemi, M. P. Pancrazi, J. Plas, M. I. Agostino, J. -F. Alexandra, B. Beaufils, J. -P. Cano, C. Hazif-Thomas, B. Kruczek, B. Laurent, B. F. Michel, A. Nieoullon, J. -P. Polydor, M. Sarazin, C. Jeandel. (2009) La prescription des antipsychotiques chez le sujet âgé. Les cahiers de l'année gérontologique 1:3, 149-163
CrossRef114
Richard G. Stefanacci, Elizabeth Cavallaro, Mark H. Beers, Donna M. Fick. (2009) Developing Explicit Positive Beers Criteria for Preferred Central Nervous System Medications in Older Adults. The Consultant Pharmacist 24:8, 601-610
CrossRef115
Jue He, Huanmin Luo, Bin Yan, Yingxin Yu, Haitao Wang, Zelan Wei, Yanbo Zhang, Haiyun Xu, Adrien Tempier, Xiaokun Li, Xin-Min Li. (2009) Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiology of Aging 30:8, 1205-1216
CrossRef116
Guk-Hee Suh. (2009) The use of atypical antipsychotics in dementia: rethinking Simpson's paradox. International Psychogeriatrics 21:04, 616
CrossRef117
Ronald Black, Barry Greenberg, J. Michael Ryan, Holly Posner, Jeffrey Seeburger, Joan Amatniek, Malca Resnick, Richard Mohs, David S. Miller, Daniel Saumier, Maria C. Carrillo, Yaakov Stern. (2009) Scales as outcome measures for Alzheimer's disease. Alzheimer's and Dementia 5:4, 324-339
CrossRef118
Mehrul Hasnain, W. Victor R. Vieweg, Mark S. Baron, Mary Beatty-Brooks, Antony Fernandez, Anand K. Pandurangi. (2009) Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism. The American Journal of Medicine 122:7, 614-622
CrossRef119
Glen I. Spielmans. (2009) The promotion of olanzapine in primary care: An examination of internal industry documents. Social Science & Medicine 69:1, 14-20
CrossRef120
Pravin Kamble, Hua Chen, Jeffrey T. Sherer, Rajender R. Aparasu. (2009) Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US. Drugs & Aging 26:6, 483-492
CrossRef121
John E. Morley. (2009) Polypharmacy in the Nursing Home. Journal of the American Medical Directors Association 10:5, 289-291
CrossRef122
Renate M. Nijk, Sytse U. Zuidema, Raymond T. C. M. Koopmans. (2009) Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia. International Psychogeriatrics 21:03, 485
CrossRef123
S. Harston. (2009) Confusion et épilepsie. Les cahiers de l'année gérontologique 1:2, 118-122
CrossRef124
Constantin Psarros, Christos G. Theleritis, Thomas J. Paparrigopoulos, Antonios M. Politis, George N. Papadimitriou. (2009) Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis. International Journal of Geriatric Psychiatry 24:5, 518-522
CrossRef125
Clive G. Ballard, Serge Gauthier, Jeffrey L. Cummings, Henry Brodaty, George T. Grossberg, Philippe Robert, Constantine G. Lyketsos. (2009) Management of agitation and aggression associated with Alzheimer disease. Nature Reviews Neurology 5:5, 245-255
CrossRef126
Rajesh Tampi, Rehan Aziz, Joshua Kantrowitz, Kirsten M Wilkins, Kristina Zdanys, Sunanda Muralee, Rajesh Tampi. 2009. Carbamazepine and oxcarbazepine for the treatment of behavioural and psychological symptoms of dementia (BPSD). .
CrossRef127
Chanaka Wijeratne, Peter Harris. (2009) Late life depression and dementia: a mental health literacy survey of Australian general practitioners. International Psychogeriatrics 21:02, 330
CrossRef128
Gabriele Meyer, Sascha Köpke, Burkhard Haastert, Ingrid Mühlhauser. (2009) Restraint use among nursing home residents: cross-sectional study and prospective cohort study. Journal of Clinical Nursing 18:7, 981-990
CrossRef129
Gary S. Stevenson, Muhammad A. Khan, Nagarajan Perumal. (2009) A psychiatric intensive care unit for older adults: an interval comparison of admissions. International Psychogeriatrics 21:02, 278
CrossRef130
Daniel W. O'Connor, David Ames, Betina Gardner, Madeleine King. (2009) Psychosocial treatments of behavior symptoms in dementia: a systematic review of reports meeting quality standards. International Psychogeriatrics 21:02, 225
CrossRef131
Laura H. P. Eggermont, Kerst de Vries, Erik J. A. Scherder. (2009) Psychotropic medication use and cognition in institutionalized older adults with mild to moderate dementia. International Psychogeriatrics 21:02, 286
CrossRef132
Scott A. Irwin. (2009) A call for simple and rational palliative medicine psychotropic prescribing guidelines: Response to Barnhorst et al. ( Palliative & Supportive Care, Volume 6, Number 1, 2008). Palliative and Supportive Care 7:01, 3
CrossRef133
Monica Mathys, Amie Blaszczyk, Anthony Busti. (2009) <b>Incidence of Abnormal Metabolic Parameters and Weight Gain Induced by Atypical Antipsychotics in Elderly Patients with Dementia Research and Reports</b>. The Consultant Pharmacist 24:3, 201-209
CrossRef134
Alessandro Nobili, Luca Pasina, Silvia Trevisan, Emma Riva, Ugo Lucca, Mauro Tettamanti, Marina Matucci, Massimo Tarantola. (2009) Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. International Clinical Psychopharmacology 24:2, 97-104
CrossRef135
Stewart G. Albert, George T. Grossberg, Papan J. Thaipisuttikul, Jarod Scouby, Erin Green. (2009) Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study. Journal of the American Medical Directors Association 10:2, 115-119
CrossRef136
David Q. Beversdorf, Michael J. Tomasi. (2009) Effect of Luteinizing Hormone-Releasing Hormone Agonists on Behavior in a Patient With Dementia. Journal of Clinical Psychopharmacology 29:1, 101-102
CrossRef137
Clive Ballard, Maria Luisa Hanney, Megan Theodoulou, Simon Douglas, Rupert McShane, Katja Kossakowski, Randeep Gill, Edmund Juszczak, Ly-Mee Yu, Robin Jacoby. (2009) The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. The Lancet Neurology 8:2, 151-157
CrossRef138
Michael J. Serby, David M. Roane, Melinda S. Lantz, Adam J. Cohen, Alisa Turok, Theresa E. Perlis. (2009) Current Attitudes Regarding Treatment of Agitation and Psychosis in Dementia. American Journal of Geriatric Psychiatry 17:2, 174
CrossRef139
Schneeweiss, Sebastian, Avorn, Jerry, . (2009) Antipsychotic Agents and Sudden Cardiac Death — How Should We Manage the Risk?. New England Journal of Medicine 360:3, 294-296
Full Text140
Julie S. Young, James A. Bourgeois, Donald M. Hilty, Kimberly A. Hardin. (2009) Sleep in hospitalized medical patients, Part 2: Behavioral and pharmacological management of sleep disturbances. Journal of Hospital Medicine 4:1, 50-59
CrossRef141
Michael Bird, Robert H. Llewellyn-Jones, Ailsa Korten. (2009) An evaluation of the effectiveness of a case-specific approach to challenging behaviour associated with dementia†. Aging & Mental Health 13:1, 73-83
CrossRef142
Sube Banerjee, Kritika Samsi, Charles D. Petrie, Jose Alvir, Michael Treglia, Ellias M. Schwam, Megan del Valle. (2009) What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. International Journal of Geriatric Psychiatry 24:1, 15-24
CrossRef143
Martin List, Tillmann Supprian. (2009) Inadäquate Vokalisationen bei Demenzkranken. Zeitschrift für Gerontopsychologie & -psychiatrie 22:2, 111-118
CrossRef144
Edward Alan Miller, Lon S. Schneider, Robert A. Rosenheck. (2009) Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer's disease. International Journal of Geriatric Psychiatry 24:1, 96-105
CrossRef145
Toru Kinoshita. (2009) The issues of the medicine on dementia in community. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 46:3, 207-210
CrossRef146
BG Pollock, CE Forsyth, RR Bies. (2009) The Critical Role of Clinical Pharmacology in Geriatric Psychopharmacology. Clinical Pharmacology & Therapeutics 85:1, 89-93
CrossRef147
Philip S Wang, Robert Heinssen, Molly Oliveri, Ann Wagner, Wayne Goodman. (2009) Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders. Neuropsychopharmacology 34:1, 204-212
CrossRef148
Pierre Thomas, Köksal Alptekin, Mihai Gheorghe, Mauro Mauri, José Manuel Olivares, Michael Riedel. (2009) Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia. CNS Drugs 23:3, 193-212
CrossRef149
Thierry Voisin, Bruno Vellas. (2009) Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease. Drugs & Aging 26:2, 135-144
CrossRef150
Edward Alan Miller, Lon S. Schneider, Arthur Zbrozek, Robert A. Rosenheck. (2008) Sociodemographic and Clinical Correlates of Utility Scores in Alzheimer's Disease. Value in Health 11:7, 1120-1130
CrossRef151
Manfred Gogol. (2008) Das Delir im höheren Lebensalter. Zeitschrift für Gerontologie und Geriatrie 41:6, 431-439
CrossRef152
N. A. Aziz, M. A. Marck, H. Pijl, M. G. M. Olde Rikkert, B. R. Bloem, R. A. C. Roos. (2008) Weight loss in neurodegenerative disorders. Journal of Neurology 255:12, 1872-1880
CrossRef153
David S. Knopman. (2008) Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease. Cognitive and Behavioral Neurology 21:4, 197-201
CrossRef154
Robert H. Howland. (2008) Risks and Benefits of Antipsychotic Drugs in Elderly Patients with Dementia. Journal of Psychosocial Nursing and Mental Health Services 46:11, 19-23
CrossRef155
Howard S. Kirshner. (2008) Controversies in behavioral neurology: The use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia. Current Neurology and Neuroscience Reports 8:6, 471-474
CrossRef156
Yan Feng, Bruce G. Pollock, Kim Coley, Stephen Marder, Del Miller, Margaret Kirshner, Manickam Aravagiri, Lon Schneider, Robert R. Bies. (2008) Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. British Journal of Clinical Pharmacology
CrossRef157
Karleen M McNeal, Renee P Meyer, Karen Lukacs, Anna Senseney, Jacob Mintzer. (2008) Using risperidone for Alzheimer's dementia-associated psychosis. Expert Opinion on Pharmacotherapy 9:14, 2537-2543
CrossRef158
Steven L. Dubovsky, Amelia N. Dubovsky. (2008) Mood Disorders and the Outcome of Suicidal Thoughts and Attempts. Critical Care Clinics 24:4, 857-874
CrossRef159
Jean-François Locca, Christophe J. Büla, Serge Zumbach, Olivier Bugnon. (2008) Pharmacological Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) in Nursing Homes: Development of Practice Recommendations in a Swiss Canton. Journal of the American Medical Directors Association 9:8, 611-611.e10
CrossRef160
John Tiller, David Ames, Henry Brodaty, Gerard Byrne, Sudarshan Chawla, Graeme Halliday, John Snowdon, Graham Hepworth, Peter McArdle, Isaac Schweitzer. (2008) Antipsychotic use in the elderly: What doctors say they do, and what they do. Australasian Journal on Ageing 27:3, 134-142
CrossRef161
Eva Mann, Gabriele Meyer. (2008) Medikamentöse Freiheitsbeschränkung in Pflegeheimen im Bundesland Vorarlberg, Österreich: Analyse der ersten Meldungen und Implikationen für eine zukünftige sachgerechte Verwirklichung der gesetzlichen Meldepflicht. Wiener Medizinische Wochenschrift 158:17-18, 489-492
CrossRef162
Bruce Sutor, Keith G. Rasmussen. (2008) Electroconvulsive Therapy for Agitation in Alzheimer Disease. The Journal of ECT 24:3, 239-241
CrossRef163
Sabine Ruths, Jørund Straand, Harald A. Nygaard, Dag Aarsland. (2008) Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--The Bergen District Nursing Home Study (BEDNURS). International Journal of Geriatric Psychiatry 23:9, 889-895
CrossRef164
Shinsuke Matsuzaki, Masaya Tohyama. (2008) Regulation of pituitary adenylyl cyclase-activating polypeptide (PACAP, ADCYAP1: adenylyl cyclase-activating polypeptide 1) in the treatment of schizophrenia. Expert Opinion on Therapeutic Targets 12:9, 1097-1108
CrossRef165
Hugo Lövheim, Stig Karlsson, Yngve Gustafson. (2008) The use of central nervous system drugs and analgesics among very old people with and without dementia. Pharmacoepidemiology and Drug Safety 17:9, 912-918
CrossRef166
Jiska Cohen-Mansfield, Barbara Jensen. (2008) Nursing Home Physicians' Knowledge Of and Attitudes Toward Nonpharmacological Interventions for Treatment of Behavioral Disturbances Associated With Dementia. Journal of the American Medical Directors Association 9:7, 491-498
CrossRef167
Oliver Bembom, Mark J. van der Laan. (2008) Analyzing sequentially randomized trials based on causal effect models for realistic individualized treatment rules. Statistics in Medicine 27:19, 3689-3716
CrossRef168
Hugo Lövheim, Per-Olof Sandman, Stig Karlsson, Yngve Gustafson. (2008) Behavioral and psychological symptoms of dementia in relation to level of cognitive impairment. International Psychogeriatrics 20:04,
CrossRef169
Camilla Haw, Jean Stubbs, Graeme Yorston. (2008) Antipsychotics for BPSD: an audit of prescribing practice in a specialist psychiatric inpatient unit. International Psychogeriatrics 20:04,
CrossRef170
Joel E. Streim, Anton P. Porsteinsson, Christopher D. Breder, René Swanink, Ronald Marcus, Robert McQuade, William H. Carson. (2008) A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease. American Journal of Geriatric Psychiatry 16:7, 537-550
CrossRef171
Jean-François Locca, Christophe J. Büla, Serge Zumbach, Oliver Bugnon. (2008) Pharmacological Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) in Nursing Homes: Development of Practice Recommendations in a Swiss Canton. Journal of the American Medical Directors Association 9:6, 439-448
CrossRef172
Antonis M. Politis, George N. Papadimitriou, Christos G. Theleritis, Constantin Psarros, Constantin R. Soldatos. (2008) Combination therapy with amisulpride and antidepressants: Clinical observations in case series of elderly patients with psychotic depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32:5, 1227-1230
CrossRef173
Carmina G Bernardo, Vivek Singh, Peter M Thompson. (2008) Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders. Expert Opinion on Drug Safety 7:4, 435-445
CrossRef174
Helen Lavretsky. (2008) Neuropsychiatric Symptoms in Alzheimer Disease and Related Disorders: Why Do Treatments Work in Clinical Practice but Not in the Randomized Trials?. American Journal of Geriatric Psychiatry 16:7, 523-527
CrossRef175
I Cancelli, L Valentinis, G Merlino, M Valente, GL Gigli. (2008) Drugs with Anticholinergic Properties as a Risk Factor for Psychosis in Patients Affected by Alzheimer’s Disease. Clinical Pharmacology & Therapeutics 84:1, 63-68
CrossRef176
Johanne Monette, Nathalie Champoux, Michèle Monette, Lynn Fournier, Christina Wolfson, Guillaume Galbaud du Fort, Nadia Sourial, Jean-Pierre Le Cruguel, Brian Gore. (2008) Effect of an interdisciplinary educational program on antipsychotic prescribing among nursing home residents with dementia. International Journal of Geriatric Psychiatry 23:6, 574-579
CrossRef177
Erik K. Fromme, Mark T. Hughes, Francis C. Brokaw, Kenneth E. Rosenfeld, Robert M. Arnold. (2008) Update in Palliative Medicine 2008. Journal of Palliative Medicine 11:5, 769-775
CrossRef178
Praveen Dayalu, Kelvin L Chou. (2008) Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opinion on Pharmacotherapy 9:9, 1451-1462
CrossRef179
A. Wood-Mitchell, I. A. James, A. Waterworth, A. Swann, C. Ballard. (2008) Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. Age and Ageing 37:5, 547-552
CrossRef180
J. J. Jalbert, L. A. Daiello, K. L. Lapane. (2008) Dementia of the Alzheimer Type. Epidemiologic Reviews 30:1, 15-34
CrossRef181
S. Gauthier, H. Loft, J. Cummings. (2008) Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. International Journal of Geriatric Psychiatry 23:5, 537-545
CrossRef182
Walter G. Deberdt, Alan Siegal, Jonna Ahl, Adam L. Meyers, Ronald Landbloom. (2008) Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis. International Journal of Geriatric Psychiatry 23:4, 364-369
CrossRef183
D. Paleacu, Y. Barak, I. Mirecky, D. Mazeh. (2008) Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. International Journal of Geriatric Psychiatry 23:4, 393-400
CrossRef184
Dilip V Jeste, Dan Blazer, Daniel Casey, Thomas Meeks, Carl Salzman, Lon Schneider, Pierre Tariot, Kristine Yaffe. (2008) ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia. Neuropsychopharmacology 33:5, 957-970
CrossRef185
Deborah Antai-Otong. (2008) The Art of Prescribing Pharmacological Management of Psychosis in Alzheimer's Disease: Clinical Challenges Associated With Second-Generation Antipsychotic Medications. Perspectives In Psychiatric Care 44:2, 120-123
CrossRef186
N. Mukadam, C. W. Ritchie, E. L. Sampson. (2008) Cholinesterase inhibitors for delirium: what is the evidence?. International Psychogeriatrics 20:02,
CrossRef187
Quynh-anh Nguyen, Carol Paton. (2008) The use of aromatherapy to treat behavioural problems in dementia. International Journal of Geriatric Psychiatry 23:4, 337-346
CrossRef188
Alfredo Raglio, Giuseppe Bellelli, Daniela Traficante, Marta Gianotti, Maria Chiara Ubezio, Daniele Villani, Marco Trabucchi. (2008) Efficacy of Music Therapy in the Treatment of Behavioral and Psychiatric Symptoms of Dementia. Alzheimer Disease & Associated Disorders 22:2, 158-162
CrossRef189
B. Álvarez-Fernandez, F. Formiga, R. Gomez. (2008) Delirium in hospitalised older persons: Review. The Journal of Nutrition Health and Aging 12:4, 246-251
CrossRef190
Laura N. Gitlin, Laraine Winter, Janice Burke, Nancy Chernett, Marie P. Dennis, Walter W. Hauck. (2008) Tailored Activities to Manage Neuropsychiatric Behaviors in Persons With Dementia and Reduce Caregiver Burden: A Randomized Pilot Study. American Journal of Geriatric Psychiatry 16:3, 229-239
CrossRef191
John E. Morley. (2008) Managing Persons with Dementia in the Nursing Home: High Touch Trumps High Tech. Journal of the American Medical Directors Association 9:3, 139-146
CrossRef192
Elda Jano, Michael Johnson, Hua Chen, Rajender R. Aparasu. (2008) Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996–2004. Current Medical Research and Opinion 24:3, 709-716
CrossRef193
Paul J. Drinka. (2008) Medications Prescribed by Specialists in Nursing Homes. Journal of the American Medical Directors Association 9:3, 137-138
CrossRef194
Andrea Gruneir, Kate L. Lapane, Susan C. Miller, Vincent Mor. (2008) Is Dementia Special Care Really Special? A New Look at an Old Question. Journal of the American Geriatrics Society 56:2, 199-205
CrossRef195
Donna M. Fick, Lorraine C. Mion, Mark H. Beers, Jennifer L. Waller. (2008) Health outcomes associated with potentially inappropriate medication use in older adults. Research in Nursing & Health 31:1, 42-51
CrossRef196
Michael J Passmore, David M Gardner, Yvette Polak, Kiran Rabheru. (2008) Alternatives to Atypical Antipsychotics for the Management of Dementia-Related Agitation. Drugs & Aging 25:5, 381-398
CrossRef197
Peter M. Haddad, Serdar M. Dursun. (2008) Neurological complications of psychiatric drugs: clinical features and management. Human Psychopharmacology: Clinical and Experimental 23:S1, S15-S26
CrossRef198
Martin R. Farlow, Michael L. Miller, Vojislav Pejovic. (2008) Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations. Dementia and Geriatric Cognitive Disorders 25:5, 408-422
CrossRef199
Lauren B. Ozbolt, Miguel A. Paniagua, Robert M. Kaiser. (2008) Atypical Antipsychotics for the Treatment of Delirious Elders. Journal of the American Medical Directors Association 9:1, 18-28
CrossRef200
Stephanie Kirbach, Kit Simpson, Paul J Nietert, Jacobo Mintzer. (2008) A Markov Model of the Cost Effectiveness of Olanzapine Treatment for Agitation and Psychosis??in Alzheimer??s Disease. Clinical Drug Investigation 28:5, 291-303
CrossRef201
Yunie Kim, Kirsten M Wilkins, Rajesh R Tampi. (2008) Use of Gabapentin in the Treatment of Behavioural and Psychological Symptoms of Dementia. Drugs & Aging 25:3, 187-196
CrossRef202
C. Hommet, K. Mondon, V. Camus, B. De Toffol, T. Constans. (2008) Epilepsy and Dementia in the Elderly. Dementia and Geriatric Cognitive Disorders 25:4, 293-300
CrossRef203
PAOLA ROCCA, FEDERICA MARINO, CRISTIANA MONTEMAGNI, DAVIDE PERRONE, FILIPPO BOGETTO. (2007) Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: Preliminary findings from a naturalistic, retrospective study. Psychiatry and Clinical Neurosciences 61:6, 622-629
CrossRef204
Leon Flicker, Osvaldo P. Almeida. (2007) Commentary. International Psychogeriatrics 19:06,
CrossRef205
R. T. C. M. Koopmans. (2007) Worden psychofarmaca in het verpleeghuis te vaak voorgeschreven?. Tijdschrift voor Gerontologie en Geriatrie, 2007 38:6, 238-241
CrossRef206
E. E. Femia, S. H. Zarit, M. A. P. Stephens, R. Greene. (2007) Impact of Adult Day Services on Behavioral and Psychological Symptoms of Dementia. The Gerontologist 47:6, 775-788
CrossRef207
Werner Kissling, Per Glue, Rossella Medori, Steve Simpson. (2007) Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Human Psychopharmacology: Clinical and Experimental 22:8, 505-513
CrossRef208
Gina Shaw. (2007) Negative Donepezil Trial Underscores Dearth of Behavioral Treatments for AD. Neurology Today 7:23, 31-32
CrossRef209
O. Bembom, M. J. van der Laan. (2007) Statistical Methods for Analyzing Sequentially Randomized Trials. JNCI Journal of the National Cancer Institute 99:21, 1577-1582
CrossRef210
Jean Hollis, David Grayson, Loelle Forrester, Henry Brodaty, Stephen Touyz, Robert Cumming. (2007) Antipsychotic Medication Dispensing and Risk of Death in Veterans and War Widows 65 Years and Older. American Journal of Geriatric Psychiatry 15:11, 932-941
CrossRef211
Jessica Broadway, Jacobo Mintzer. (2007) The many faces of psychosis in the elderly. Current Opinion in Psychiatry 20:6, 551-558
CrossRef212
Bruce G. Pollock, Benoit H. Mulsant, Jules Rosen, Sati Mazumdar, Richard E. Blakesley, Patricia R. Houck, Kimberly A. Huber. (2007) A Double-Blind Comparison of Citalopram and Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Dementia. American Journal of Geriatric Psychiatry 15:11, 942-952
CrossRef213
Clive Ballard. (2007) Agitation and Psychosis in Dementia. American Journal of Geriatric Psychiatry 15:11, 913-917
CrossRef214
Ladson Hinton, Carol E. Franz, Geetha Reddy, Yvette Flores, Richard L. Kravitz, Judith C. Barker. (2007) Practice Constraints, Behavioral Problems, and Dementia Care: Primary Care Physicians’ Perspectives. Journal of General Internal Medicine 22:11, 1487-1492
CrossRef215
Howard, Robert J., Juszczak, Edmund, Ballard, Clive G., Bentham, Peter, Brown, Richard G., Bullock, Roger, Burns, Alistair S., Holmes, Clive, Jacoby, Robin, Johnson, Tony, Knapp, Martin, Lindesay, James, O'Brien, John T., Wilcock, Gordon, Katona, Cornelius, Jones, Roy W., DeCesare, Julia, Rodger, Michaela. (2007) Donepezil for the Treatment of Agitation in Alzheimer's Disease. New England Journal of Medicine 357:14, 1382-1392
Full Text216
Yaffe, Kristine, . (2007) Treatment of Neuropsychiatric Symptoms in Patients with Dementia. New England Journal of Medicine 357:14, 1441-1443
Full Text217
William H. Shrank, Jennifer M. Polinski, Jerry Avorn. (2007) Quality Indicators for Medication Use in Vulnerable Elders. Journal of the American Geriatrics Society 55, S373-S382
CrossRef218
Denise G. Feil, Catherine MacLean, David Sultzer. (2007) Quality Indicators for the Care of Dementia in Vulnerable Elders. Journal of the American Geriatrics Society 55, S293-S301
CrossRef219
Bret Rutherford, Joel Sneed, Marissa Miyazaki, Rachel Eisenstadt, Devangere Devanand, Harold Sackeim, Steven Roose. (2007) An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. International Journal of Geriatric Psychiatry 22:10, 986-991
CrossRef220
Tony Mets, Maurits Vandewoude, Jean Jacquy, Anne Deblander, Karen MacDonald, Anne Sloesen, Ivo Abraham. (2007) Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease:the Belgian FExT study. Current Medical Research and Opinion 23:10, 2485-2501
CrossRef221
Steven A. Levenson, John E. Morley. (2007) Evidence Rocks in Long-term Care, But Does It Roll?. Journal of the American Medical Directors Association 8:8, 493-501
CrossRef222
HIROSHI KATAGAI, NORIO YASUI-FURUKORI, ATSUHIRO KIKUCHI, SUNAO KANEKO. (2007) Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature. Psychiatry and Clinical Neurosciences 61:5, 568-570
CrossRef223
Barbara J Zarowitz. (2007) Limits of evidence-based medicine in older adults. Aging Health 3:5, 601-610
CrossRef224
Camilla Haw, Jean Stubbs. (2007) Off-label use of antipsychotics: are we mad?. Expert Opinion on Drug Safety 6:5, 533-545
CrossRef225
M. Rainer, M. Haushofer, H. Pfolz, C. Struhal, W. Wick. (2007) Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: Efficacy, safety and cognitive function. European Psychiatry 22:6, 395-403
CrossRef226
Gunvant K Thaker. (2007) Schizophrenia endophenotypes as treatment targets. Expert Opinion on Therapeutic Targets 11:9, 1189-1206
CrossRef227
D. Fick, A. Kolanowski, J. Waller. (2007) High prevalence of central nervous system medications in community-dwelling older adults with dementia over a three-year period. Aging & Mental Health 11:5, 588-595
CrossRef228
Barbara J. Messinger-Rapport, John E. Morley, David R. Thomas, Julie K. Gammack. (2007) Intensive Session: New Approaches to Medical Issues in Long-Term Care. Journal of the American Medical Directors Association 8:7, 421-433
CrossRef229
Lisa J. Miller. (2007) <b>The Use of Cognitive Enhancers in Behavioral Disturbances of Alzheimer's Disease</b>. The Consultant Pharmacist 22:9, 754-762
CrossRef230
Brendan J. Kelley, Ronald C. Petersen. (2007) Alzheimer's Disease and Mild Cognitive Impairment. Neurologic Clinics 25:3, 577-609
CrossRef231
Manju T. Beier, Caren McHenry Martin. (2007) <b>Gradual Dose Reduction and Medication Tapering: A Clinical Perspective</b>. The Consultant Pharmacist 22:8, 628-644
CrossRef232
Arun V Ravindran, Cheryl Bradbury, Martha McKay, Tricia L da Silva. (2007) Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders. Expert Opinion on Pharmacotherapy 8:11, 1693-1710
CrossRef233
S Schneeweiss. (2007) Developments in Post-marketing Comparative Effectiveness Research. Clinical Pharmacology & Therapeutics 82:2, 143-156
CrossRef234
Peter V Rabins, Constantine G Lyketsos. (2007) Pharmacotherapy of neuropsychiatric symptoms: opportunities, challenges and current prospects. Nature Clinical Practice Neurology 3:5, 239-239
CrossRef235
N. Monnier, G. Ardiet. (2007) Prescription de neuroleptiques en maison de retraite (Étude de 2200 prescriptions). Annales Médico-psychologiques, revue psychiatrique 165:4, 258-262
CrossRef236
Clive Ballard, Jane Fossey, Samantha Sharp. (2007) Antipsychotics in patients with Alzheimer's disease—what is their clinical value?. Nature Clinical Practice Neurology 3:5, 248-249
CrossRef237
(2007) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 22:5, 503-510
CrossRef238
Kelvin L Chou, Joseph H Friedman. (2007) Drug-induced parkinsonism in the elderly. Future Neurology 2:3, 307-316
CrossRef239
PATRICIA R. RECUPERO, SAMARA E. RAINEY. (2007) Managing Risk When Considering the Use of Atypical Antipsychotics for Elderly Patients with Dementia-Related Psychosis. Journal of Psychiatric Practice 13:3, 143-152
CrossRef240
Joseph Shega, Linda Emanuel, Lisa Vargish, Stacie K. Levine, Heide Bursch, Keela Herr, Jordan F. Karp, Debra K. Weiner. (2007) Pain in Persons With Dementia: Complex, Common, and Challenging. The Journal of Pain 8:5, 373-378
CrossRef241
Stanley N Caroff, E Cabrina Campbell, Kenneth A Sullivan. (2007) Neuroleptic malignant syndrome in elderly patients. Expert Review of Neurotherapeutics 7:4, 423-431
CrossRef242
Donald R. Royall. (2007) CATIE'S LESSONS. Journal of the American Geriatrics Society 55:4, 636-637
CrossRef243
E. Does. (2007) Het effect van atypische, antipsychotische geneesmiddelen bij patiënten met de ziekte van Alzheimer. Medisch-Farmaceutische Mededelingen 45:4, 108-109
CrossRef244
Manju T Beier. (2007) Treatment Strategies for the Behavioral Symptoms of Alzheimer's Disease: Focus on Early Pharmacologic Intervention. Pharmacotherapy 27:3, 399-411
CrossRef245
Barbara R Sommer, Howard H Fenn, Terence A Ketter. (2007) Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin. Expert Opinion on Drug Safety 6:2, 133-145
CrossRef246
Benjamin Shapiro, James Randy Mervis. (2007) Distinguishing delirium and dementia. Aging Health 3:1, 33-48
CrossRef247
(2007) Atypical Antipsychotic Drugs and Alzheimer's Disease. New England Journal of Medicine 356:4, 416-418
Full Text248
Peter M Haddad, Sonu G Sharma. (2007) Adverse Effects of Atypical Antipsychotics. CNS Drugs 21:11, 911-936
CrossRef249
Jean Hollis, Loelle Forrester, Henry Brodaty, Stephen Touyz, Robert Cumming, David Grayson. (2007) Risk of death associated with antipsychotic drug dispensing in residential aged care facilities. Australian and New Zealand Journal of Psychiatry 41:9, 751-758
CrossRef250
AHSAN Y. KHAN, MALIK NAZ KALIMUDDIN, JACK M. GORMAN. (2007) Neuropsychiatric Manifestations of Phenytoin Toxicity in an Elderly Patient. Journal of Psychiatric Practice 13:1, 49-54
CrossRef251
Subramoniam Madhusoodanan, Payal Shah, Ronald Brenner, Sanjay Gupta. (2007) Pharmacological Treatment of the Psychosis of Alzheimer???s Disease. CNS Drugs 21:2, 101-115
CrossRef252
Tetsuaki Arai. (2007) Practical clinical use of therapeutic agents for Alzheimer′s disease. Folia Pharmacologica Japonica 130:6, 494-498
CrossRef253
Raymond C. Love, Warachal E. Faison, David L. Sultzer. (2006) An Evidence-Based Approach to Optimizing the Management of Psychotic Disorders in the Long-Term Care Setting. The Consultant Pharmacist 21:0, 1-28
CrossRef254
Kurt Samson. (2006) NEWER ANTIPSYCHOTICS FALL SHORT FOR MANY WITH ALZHEIMERʼS DEMENTIA, NIMH STUDY FINDS. Neurology Today 6:21, 5-6
CrossRef255
(2006) News in brief. Nature Reviews Drug Discovery 5:11, 884-885
CrossRef256
Karlawish, Jason, . (2006) Alzheimer's Disease — Clinical Trials and the Logic of Clinical Purpose. New England Journal of Medicine 355:15, 1604-1606
Full Text
- Letters
